GoL Lung & GoL Colon & GoL Breast Total Solution of Integrated Precision Medicine Service
Model: GoL Lung/Colon/Breast & GoL Pan-Cancer
Category: Gene & Biotech Services
Exhibitor: KIM FOREST ENTERPRISE CO., LTD.
Booth No: M308
DNA would be degraded into circulating free DNA fragments (cfDNA), which will release to the blood plasma. Similarly, circulating tumor DNA (ctDNA), one of the family cfDNA, is tumor-derived fragmented DNA in the bloodstream. Therefore, elevated level of ctDNA is an index to find cancer cells, especially in advanced cancer.
GoL cfDNA Assay is part of the complete research solution to detect ctDNA in cfDNA. It provides an efficient approach to detect cfDNA from the plasma fraction of a single tube of whole blood. The assay enables doctors to analyze single nucleotide variants and short indels, frequently mutated in non-small cell lung cancer (NSCLC), colon cancers, and breast cancer, with the a limit of detection down to ~0.1%. In GoL cfDNA Assay, such innovative tag sequencing technology would give valid information for treatment selection and recurrence monitoring.
Highly Validated Human Primary Cell Culture Models of Disease and Biology
GoL Life Non-invasive genomewide assessment
GoL Comprehensive & GoL Focus Total Solution of Integrated Precision Medicine Service
BROMOscan Bromodomain Screening & Profiling
GoL BRCA Total Solution of Integrated Precision Medicine Service
Products you may be interested in